Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
About 40% of hormone-positive breast cancers in postmenopausal women might be linked to excess body fat, researchers reported ...
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
About 6% of Leqembi is thrown away because there’s leftover drug after a dose is drawn to match a person’s weight Adding a 75-milligram vial could reduce waste by 74% and save Medicare as much ...
Medpage Today on MSN2d
Alzheimer's Drug in Smaller Vial Sizes Could Save Medicare Hundreds of MillionsAn estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save ...
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...
Biogen (BIIB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback